Aus Pubmed

Clin Case Rep. 2024 May 31;12(6):e9037. doi: 10.1002/ccr3.9037. eCollection 2024 Jun. ABSTRACT KEY CLINICAL MESSAGE: The use of phototherapy is highly effective in treating various skin diseases. In this study, the aim is to present vesicular and blister lesions in patients treated with UVB for psoriasis. It is advisable to consider the possibility of BSLE in cases of vesiculobullous lesions following phototherapy, along with other potential diagnoses. ABSTRACT: Bullous systemic lupus erythemato

Arch Dermatol Res. 2024 May 18;316(5):181. doi: 10.1007/s00403-024-02978-2. ABSTRACT Background An increasing body of observational studies has indicated a potential link between allergic diseases, namely atopic dermatitis (AD), allergic rhinitis (AR), allergic asthma (AA), and psoriasis (PSO) as well as psoriatic arthritis (PSA). However, the presence and causal direction of this association remain uncertain. Methods We conducted two-sample Mendelian randomization (TSMR) analyses utilizing summ

J Am Acad Dermatol. 2024 May 16:S0190-9622(24)00753-9. doi: 10.1016/j.jaad.2024.05.021. Online ahead of print. NO ABSTRACT PMID:38762009 | DOI:10.1016/j.jaad.2024.05.021 Den ganzen Artikel lesen

J Allergy Clin Immunol. 2024 May 16:S0091-6749(24)00506-2. doi: 10.1016/j.jaci.2024.05.008. Online ahead of print. ABSTRACT The routine use of targeted systemic immunomodulatory therapies has transformed outcomes for people with severe psoriasis, with skin clearance (clinical remission) rates up to 60% at one year of biologic treatment. However, psoriasis may recur following drug withdrawal, and so patients tend to remain on costly treatment indefinitely. Here, we review research into the 'infla

Int Immunopharmacol. 2024 May 17;134:112261. doi: 10.1016/j.intimp.2024.112261. Online ahead of print. ABSTRACT BACKGROUND: Psoriasis, a chronic inflammatory condition of the skin, is characterized by an atypical proliferation of epidermal keratinocytes and immune cell infiltration. Orientin is a flavonoid monomer with potent anti-inflammatory activities. However, the therapeutic effects of orientin on psoriasis and the underlying mechanisms have not been elucidated. OBJECTIVE: To investigate th

Lipids Health Dis. 2024 May 17;23(1):143. doi: 10.1186/s12944-024-02123-y. ABSTRACT BACKGROUND: Lipid accumulation product (LAP) is an accessible and relatively comprehensive assessment of obesity that represents both anatomical and physiological lipid accumulation. Obesity and psoriasis are potentially related, according to previous research. Investigating the relationship between adult psoriasis and the LAP index was the goal of this study. METHODS: This is a cross-sectional study based on dat

BMJ Open. 2024 May 16;14(5):e079540. doi: 10.1136/bmjopen-2023-079540. ABSTRACT OBJECTIVES: Patients' preferences, values and contexts are important elements of the shared decision-making (SDM) process. We captured those elements into the concept of 'personal perspective elicitation' (PPE), which reflects the need to elicit patients' preferences, values and contexts in patient-clinician conversations. We defined PPE as: 'the disclosure (either elicited by the clinician or spontaneously expressed

Int Immunopharmacol. 2024 May 16;134:112225. doi: 10.1016/j.intimp.2024.112225. Online ahead of print. ABSTRACT Itolizumab is a humanized monoclonal antibody that selectively targets the CD6-ALCAM pathway. This article reports on the safety and efficacy of itolizumab in the treatment of moderate-to-severe plaque psoriasis in a clinical study conducted in Cuba in the setting of an expanded-access program (EAP). The study included 84 patients who had previously received conventional anti-psoriatic

Rheumatology (Oxford). 2024 May 17:keae263. doi: 10.1093/rheumatology/keae263. Online ahead of print. ABSTRACT OBJECTIVE: To present the characteristics of patients with potential difficult-to-treat (D2T) psoriatic arthritis (PsA). METHODS: We used data from the Greek multicentre registry of PsA patients. D2T-PsA was defined as follows: patients with at least 6-months disease duration, who have failed to at least 1 csDMARD and at least 2 bDMARDs/tsDMARDs with a different mechanism of action and

Arch Dermatol Res. 2024 May 17;316(5):176. doi: 10.1007/s00403-024-02886-5. ABSTRACT Psoriasis is a chronic immune mediated inflammatory skin disease with systemic manifestations. It has been reported that caloric restriction could improve severity of psoriasis patients. However, the mechanism of intermittent fasting effects on psoriasis has not been investigated. Caloric restriction is known to reduce the number of circulating inflammatory monocytes in a CCL2-dependent manner. However, it is st

Exp Dermatol. 2024 May;33(5):e15067. doi: 10.1111/exd.15067. ABSTRACT Patients receiving interleukin (IL)-inhibiting biologics for moderate-to-severe psoriasis (PsO) may be treated with escalated doses to optimize outcomes. This study evaluated escalation prevalence in a Japanese claims analysis of patients with PsO diagnosis preceding IL-inhibiting biologic treatment and ≥1 post-induction maintenance claim (index date) with sufficient data availability from January 2014 to May 2022. Patients wi

Medicine (Baltimore). 2024 May 10;103(19):e38055. doi: 10.1097/MD.0000000000038055. ABSTRACT Multiple studies have indicated a potential correlation between immune-mediated inflammatory diseases (IMIDs) and Frozen shoulder (FS). To explore the genetic causal relationship between IMIDs and FS using 2-sample Mendelian randomization (MR) analysis. Genome-wide association study (GWAS) summary data for FS were obtained from Green's study, while data for 10 IMIDs were sourced from the FinnGen Consorti

PLoS One. 2024 May 10;19(5):e0303058. doi: 10.1371/journal.pone.0303058. eCollection 2024. ABSTRACT BACKGROUND: Shared decision-making (SDM) refers to a collaborative process in which clinicians assist patients in making medically informed, evidence-based decisions that align with their values and preferences. There is a paucity of literature on SDM in dermatology. OBJECTIVE: We aim to assess whether male and female psoriasis patients evaluate their clinicians' engagement in SDM differently acro

Dermatol Ther (Heidelb). 2024 May 10. doi: 10.1007/s13555-024-01164-6. Online ahead of print. ABSTRACT INTRODUCTION: Real-world data on the efficacy of risankizumab (RZB) in clinical moderate-to-severe plaque psoriasis (PsO) are limited. The RAPID study assessed real-world clinical and patient-reported outcomes in RZB-treated PsO patients using data collected from dermatologists in Canada, the Czech Republic, Germany, Japan, and Poland. METHODS: This ongoing, retrospective chart review collected

Dermatol Ther (Heidelb). 2024 May 10. doi: 10.1007/s13555-024-01170-8. Online ahead of print. ABSTRACT INTRODUCTION: There are several treatment options for plaque psoriasis (PsO), but uncertainty remains around the optimal sequencing of treatments. The aims of this study were to investigate how adopting a best-treatment-first treatment sequence impacts patient outcomes and healthcare systems and to quantify the cost of treatment failure to the healthcare system. METHODS: A 3-year state-transiti

Mol Biol Rep. 2024 May 10;51(1):635. doi: 10.1007/s11033-024-09337-4. ABSTRACT BACKGROUND: Psoriasis, a chronic inflammatory skin disease, is increasingly effectively managed with the targeted immunotherapy; however, long-term immunotherapy carries health risks, and loss of response. Therefore, we need to develop the alternative treatment strategies. Mesenchymal stem/stromal cell (M.S.C.) exosomes stand out for their remarkable immunomodulatory properties, gaining widespread recognition. This st

Ital J Dermatol Venerol. 2024 May 10. doi: 10.23736/S2784-8671.24.07666-7. Online ahead of print. ABSTRACT SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who t

Ital J Dermatol Venerol. 2024 May 10. doi: 10.23736/S2784-8671.24.07664-3. Online ahead of print. ABSTRACT SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who t

J Clin Aesthet Dermatol. 2024 May;17(5 Suppl 2):S7-S10. NO ABSTRACT PMID:38726208 | PMC:PMC11078528 Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2024 May 9. doi: 10.1007/s13555-024-01162-8. Online ahead of print. ABSTRACT INTRODUCTION: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Although the US prescribing information for brodalumab includes a boxed warning regarding suicidal ideatio

Nat Commun. 2024 May 9;15(1):3901. doi: 10.1038/s41467-024-48288-z. ABSTRACT Activation of the NF-κB pathway is strictly regulated to prevent excessive inflammatory and immune responses. In a well-known negative feedback model, IκBα-dependent NF-κB termination is a delayed response pattern in the later stage of activation, and the mechanisms mediating the rapid termination of active NF-κB remain unclear. Here, we showed IκBα-independent rapid termination of nuclear NF-κB mediated by CLK2, which

Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001514. Online ahead of print. ABSTRACT BACKGROUND: Glucagon-like peptide-1 receptor (GLP1R) agonists have been approved by Food and Drug Administration for management of obesity. However, the causal relationship of GLP1R agonists (GLP1RA) with cancers still unclear. METHODS: The available cis-eQTLs for drugs target genes (GLP1R) were used as proxies for exposure to GLP1RA. Mendelian randomizations (MR) were performed to reveal the association o

Medicine (Baltimore). 2024 May 3;103(18):e38007. doi: 10.1097/MD.0000000000038007. ABSTRACT BACKGROUND: This systematic review and meta-analysis aimed to report the evaluation of the prevalence and risk of nonalcoholic fatty liver disease (NAFLD) among adult psoriatic patients in a systematic review and meta-analysis. METHODS: A comprehensive search was conducted across 4 databases of PubMed, Scopus, Cochrane Library, and Web of Science to collect relevant studies until November 30, 2023, withou

Dermatol Ther (Heidelb). 2024 May 3. doi: 10.1007/s13555-024-01160-w. Online ahead of print. ABSTRACT INTRODUCTION: Since during the COVID-19 pandemic nail psoriasis was evaluated exclusively with teledermatology, dermatologists started to face the difficulty in rating it concurrent with other onycopathies (i.e., onychotillomania and onychophagy). Thus, we aimed to improve the existing severity scores and verify the value in different clinical settings (i.e., in person vs. teledermatology (video

Skin Res Technol. 2024 May;30(5):e13718. doi: 10.1111/srt.13718. ABSTRACT INTRODUCTION: Due to the increasing prevalence of immune-mediated diseases such as psoriasis, lichen planus, rheumatoid arthritis and inflammatory bowel disease, dermatologists have turned to new biologic drugs known as DMARDs (disease-modifying anti-rheumatic drugs) in recent years. AREAS COVERED: In this study, we evaluate the immune-mediated dermatological side effects of DMARDS by reviewing and analyzing previous peer-